You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 1, 2024

~ Buy the PRIALT Drug Profile, 2024 PDF Report in the Report Store ~

PRIALT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Prialt, and when can generic versions of Prialt launch?

Prialt is a drug marketed by Tersera and is included in one NDA. There are three patents protecting this drug.

This drug has six patent family members in four countries.

The generic ingredient in PRIALT is ziconotide acetate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ziconotide acetate profile page.

DrugPatentWatch® Generic Entry Outlook for Prialt

Prialt was eligible for patent challenges on December 28, 2008.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 1, 2024. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for PRIALT
International Patents:6
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 31
Clinical Trials: 6
Patent Applications: 1,219
Drug Prices: Drug price information for PRIALT
What excipients (inactive ingredients) are in PRIALT?PRIALT excipients list
DailyMed Link:PRIALT at DailyMed
Drug patent expirations by year for PRIALT
Drug Prices for PRIALT

See drug prices for PRIALT

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PRIALT
Generic Entry Date for PRIALT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INTRATHECAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PRIALT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Albany Medical CollegePhase 4
Aaron BosterPhase 4
Jazz Pharmaceuticals

See all PRIALT clinical trials

Pharmacology for PRIALT

US Patents and Regulatory Information for PRIALT

PRIALT is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of PRIALT is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting PRIALT

Method for administering omega-conopeptide
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: ANALGESIA

Method for administering omega-conopeptide
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF PAIN

Method for administering omega-conopeptide
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: ANALGESIA

Method for administering omega-conopeptide
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF PAIN

Method for administering .omega.-conopeptide
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-002 Dec 28, 2004 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-003 Dec 28, 2004 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-002 Dec 28, 2004 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-001 Dec 28, 2004 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-003 Dec 28, 2004 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-004 Dec 28, 2004 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-004 Dec 28, 2004 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PRIALT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-003 Dec 28, 2004 ⤷  Try a Trial ⤷  Try a Trial
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-002 Dec 28, 2004 ⤷  Try a Trial ⤷  Try a Trial
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-001 Dec 28, 2004 ⤷  Try a Trial ⤷  Try a Trial
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-003 Dec 28, 2004 ⤷  Try a Trial ⤷  Try a Trial
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-001 Dec 28, 2004 ⤷  Try a Trial ⤷  Try a Trial
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-002 Dec 28, 2004 ⤷  Try a Trial ⤷  Try a Trial
Tersera PRIALT ziconotide acetate INJECTABLE;INTRATHECAL 021060-004 Dec 28, 2004 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PRIALT

See the table below for patents covering PRIALT around the world.

Country Patent Number Title Estimated Expiration
Denmark 1336409 ⤷  Try a Trial
Spain 2194998 ⤷  Try a Trial
Portugal 835126 ⤷  Try a Trial
Australia 695166 ⤷  Try a Trial
Japan 2007507538 ⤷  Try a Trial
European Patent Office 1336409 Compositions et formulations permettant de produire une analgésie et d'inhiber la progression de troubles liés à des douleurs neuropathiques (Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders) ⤷  Try a Trial
Netherlands 300201 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for PRIALT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0835126 300201 Netherlands ⤷  Try a Trial 300201, 20160626, EXPIRES: 20200220
0835126 C00835126/01 Switzerland ⤷  Try a Trial PRODUCT NAME: ZICONOTIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56855 11.04.2006
0835126 CA 2005 00033 Denmark ⤷  Try a Trial
0835126 289 Finland ⤷  Try a Trial
0835126 SPC019/2005 Ireland ⤷  Try a Trial SPC019/2005: 20060407, EXPIRES: 20200220
0835126 05C0027 France ⤷  Try a Trial PRODUCT NAME: ZICONOTIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/04/302/001 DU 20050221; REGISTRATION NO/DATE AT EEC: EU/1/04/302/001-003 DU 20050221
0835126 91181 Luxembourg ⤷  Try a Trial 91181, EXPIRES: 20200221
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.